Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
ILD
•
Diffuse Parenchymal Lung Disease
•
CTD-ILD
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Related Questions
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
When do you screen for pulmonary hypertension in ILD patients?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Does your approach to treating latent tuberculosis differ in a patient on anti-fibrotic therapy?
What protective post-op measures do you recommend for a patient with scleroderma and a history of ILD, PH, Raynaud’s and digital ischemia undergoing cardiothoracic surgery?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
What are the next steps in the management of a patient admitted with an IPF exacerbation resistant to steroid therapy?
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
